-
-
-
-
-
-
-
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak
-
-
-
-
-
-
-
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook
-
-
-
-
-
-
-
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
-
-
-
-
-
-
-
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
-
-
-
-
-
-
-
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
-
-
-
-
-
-
-
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
-
-
-
-
-
-
-
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
-
1,220,232 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

